N-(吡嗪基羰基)-L-苯基丙氨酸

N-(吡嗪基羰基)-L-苯基丙氨酸
(S)-3-Phenyl-2-(pyrazine-2-carboxamido)propanoic acid;N-(Pyrazinylcarbonyl)-L-phenylalanine;(S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO] PROPANOIC ACID;(S)-3-Phenyl-2-[[(pyrazin-2-yl)carbonyl]amino]propanoic acid;L-Phenylalanine,N-(2-pyrazinylcarbonyl)-;N-(2-Pyrazinylcarbonyl)-L-phenylalanine;N-Pyrazinylcarbonyl-;N-Pyrazinylcarbonyl-L-phenylalanine;N-PYRAZINYLCARBONYLPHENYLALANINE;(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoic acid;Bortezomib INT B;Bortezomib impurity B;Bortezomib Impurity 36;Bortezomib Acid Impurity;N-(2-pyrazinylcarbonyl)-;Bortezomib Intermediate 2;(pyrazine-2-carbonyl)-L-phenylalanine;(S)-3-phenyl-2-(pyrazine-2-carboxamido)propionic acid;(S)-3-Phenyl-2-[(pyrazine-2-carbonyl)-amino]-propionic acid;L-Phenylalanine, N-(pyrazinylcarbonyl)-;pyrazine-2-carbonylphenylalanine;L-;Bortezomi;L-Phenylalanine, N-(2-pyrazinylcarbonyl)-;Borte